Asgard Therapeutics

🌍 Join Asgard Therapeutics at BIO-EUROPE 2024 in Stockholm, Sweden, from November 4th to 6th. 🗣️ Fireside Chat with our Co-founder and CEO, Cristiana Pires Topic: "All for You": Transforming patient care with Intratumoral Therapy 📅 Date: Tuesday, November 5th  🕒 Time: 12:30 - 13:00  📍 Location: Exhibit Hall Stage You’ll also have the opportunity to meet Iveta Mikalajūnaitė, our Business Developer, during the entire event. Looking forward to connecting with you at BIO-EUROPE! 🔬✨ #BIOEUROPE2024 #CancerImmunotherapy #AsgardTherapeutics 

🌟  We are exited to share that our in vivo cell reprogramming technology has been featured in the October 2024 edition of MedNous (Evernow Publishing Ltd) under the Research Strategy section. The article, titled 'A New Cell Reprogramming Approach for Cancer', was written by our CEO and co-founder, Cristiana Pires. It explores the immunotherapy landscape, the cell reprogramming approach, and how Asgard Therapeutics is translating this technology into clinical applications. As our CEO explained: "We are genetically reprogramming cancer cells to force them to become antigen-presenting ‘traitors,’ specifically dendritic cells, which educate the patient’s immune system on how to recognise and attack the cancer cells that they used to be." Cristiana added "The advances that we and others have made suggest cellular reprogramming has real potential as an effective new way of enhancing the immune system to fight cancer: one that marries the ‘off-the-shelf’ benefits of immune checkpoint blockade drugs with the personalised response nature of autologous cell therapies." Read the full article to learn more about our work and the future of cancer treatment!

We are incredibly proud of our CEO and co-founder, Cristiana Pires, who has been recognized as one of the top six European biotech entrepreneurs to know in 2024, nominated by VCs. The article highlights Asgard Therapeutics’ first-in-class in vivo cell reprogramming technology for immuno-oncology and Series A financing. Søren Møller, Managing Partner for seed investments at Novo Holdings, emphasized: “This is basically a very exciting company working in oncology. It is a gene therapy company, and it transforms cancer cells into immune cells that present the cancer neoantigens to the immune system, and thereby enables the immune system to kill the cancer. So, it’s pretty neat biology,” He also added:  “Cristiana was one of the founding scientists, and has taken the journey from scientist to a CEO,”.

Meet Asgard Therapeutics at two major events this October! Fritiof Åkerström, Scientist at Asgard Therapeutics, will be presenting at ESGCT 2024! His presentation, titled “A cancer immunotherapy modality based on dendritic cell reprogramming in vivo,” is scheduled for October 23rd at 8:30-10:00 AM in Parallel Session 3b (Meeting Room 1). Mark your calendars! 📅 Event: ESGCT 2024  📍 Location: La Nuvola, Rome  🗓 Date: October 23rd, 8:30-10:00 AM Additionally, don’t miss the chance to connect with Xavier Catena, Senior Scientist, at the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy in Boston. He’ll be presenting a poster during Poster Session A on October 19th from 6:00-8:15 PM. 📅 Event: AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy 📍 Location: Westin Copley Place, Boston  🗓 Date: October 19th, 6:00-8:15 PM 

✨ Exciting News! ✨ We are proud to share that Asgard Therapeutics has been selected as a finalist for the European Lifestars Awards - Celebrating Life Science Leaders 2024! 🎉 We are honored to be recognized in two categories: 🏆 Biotech Company of the Year and Women-Led Business Leader of the Year, with our CEO and co-founder, Cristiana Pires, leading the way. We look forward to the awards ceremony on November 18 in London and to celebrating alongside many inspiring leaders in the life sciences industry! #Biotech #WomenInLeadership #LifeSciences #AsgardTherapeutics

🚀 Meet Asgard Therapeutics at CICON 2024 and ESMO Congress 2024! We’re excited to share that Filipe Pereira, Co-founder and Head of Innovation, will be presenting at CICON 2024. His talk, titled “A cancer immunotherapy modality based on dendritic cell reprogramming in vivo,” will take place on September 9th at 5:15 PM during Proffered Session - What’s on the Horizon: New Tools, Technologies, and Approaches in Cancer Immunotherapy, Part II. Don't miss the chance to hear the latest news from our recent publication in the journal Science! 📅 CICON 2024: September 9-11th  📍 Washington D.C.  🎙 Filipe Pereira presenting on September 9th at 5:15 PM  🤝 Fabio Rosa, Head of Research, will also be attending. You can also connect with Xiaoli Huang, Project Director in Preclinical Pharmacology, at the ESMO Congress 2024 in Barcelona! 📅 ESMO Congress 2024: September 13-17th  📍 Barcelona Spain We look forward to seeing you! #CICON2024 #ESMO2024 #AsgardTherapeutics

Check out this great article in AACR’s Cancer Discovery News about our new paper published in Science regarding Asgard’s cell reprogramming approach to cancer.    The article, Reprogramming Turns Cancer Cells into Immune Allies, can be found here: https://bit.ly/3yYmxrJ   Cancer Discovery News wrote that converting “tumor cells into immune-boosting dendritic cells shows promise in mice, setting the stage for human trials.”   The article also quoted David Tran, MD, PhD, of the University of Southern California in Los Angeles, as saying: “This paper establishes that in situ reprogramming is possible… It paves the way for potential therapeutic applications.”

Asgard Therapeutics is making fantastic progress towards taking its first-in-class approach to cancer immunotherapy into the clinic.   Last night Asgard had a milestone paper published in the journal Science. The study, co-led by Asgard and the Pereira Lab, provides proof-of-concept data demonstrating that our platform transforms tumor cells into antigen-presenting dendritic cells in living beings and not just in vitro.   The reprogrammed cells elicit “systemic and long-term antitumor immunity”, found the authors, who concluded: “Our study paves the way for human clinical trials on in vivo immune cell reprogramming for cancer immunotherapy.”   Meanwhile, Asgard is gearing up for clinical development by establishing CMC processes for scale-up manufacturing of GMP-grade AT-108 for Phase I/II trials. Click the link in the comments below to read the press release and the paper.

Asgard Therapeutics has today had a landmark paper published in the prestigious journal Science, demonstrating in vivo proof-of-concept for its first-in-class approach to cancer immunotherapy.    Novel data published in the study, co-led by the Filipe Pereira Lab at Lund University, demonstrate that our lead product AT-108 reprograms tumor cells, directly within the immunosuppressed tumor microenvironment, into antigen-presenting dendritic cells. This causes strong, antigen-specific, anti-tumor responses to be mounted, resulting in durable tumor shrinkage even upon metastatic challenge.    The study paves the way for human clinical trials of AT-108 in vivo immune cell reprogramming for cancer immunotherapy.   The graphic depicts a tumor cell being ‘unlocked’ by AT-108 and consequently transformed into an antigen-presenting dendritic cell. The dendritic cell is depicted as shining as it illuminates the way for the immune system to target ‘cold and dark’ tumors - thus generating robust, long-lasting and systemic anti-tumor responses. Graphic by Joana C. Carvalho. Click the link in the comments below to read the press release and the paper.

Curious about Asgard Therapeutics' first-in-class immunotherapy? Our lead program, AT-108, directly reprograms tumor cells into functional dendritic cells, enabling cancer cells to kick-start immune responses against themselves. Learn more about our technology and current development stage in the Biopharma Dealmaker one-pager. Find the link in the comments. Keep an eye out for some exciting news coming later this week! 🚀